Both Europe and America should rethink their approach. After the work by DeepSeek, China’s hotshot model-maker, Europe has ...

Achieving a digital transition that strengthens Europe's strategic competitiveness means addressing the persistent challenges in innovation, adoption, and technological dependency.

An ambitious new AI project has begun to take shape in Europe, with the aim of developing open-source AI models that support ...

As the first quarter of the 21st century ends with artificial intelligence (AI) taking center stage, the European Union (EU) is in the spotlight for going against the tide and setting rules for the AI ...

Viehbacher, “Biogen”) announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD (mild cognitive impairment due to ...

The review is conducted in response to a request from the European Commission, and may require the agency to update its ...

Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression and prolong the benefits of therapy TOKYO and CAMBRIDGE, Mass., Jan.

Eisai Co., Ltd. and Biogen Inc. announced that the U.S. FDA has approved a Supplemental Biologics License Application for LEQEMBI (lecanemab-irmb), allowing for once every four weeks intravenous ...

(Reuters) - The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's Alzheimer's drug Leqembi, the companies said on Monday.

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with ...